Comparison between liraglutide monotherapy and BOT therapy with long acting insulin analogue

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2011
INTERVENTION: Changing from BOT therapy to liraglutide monotherapy. Reconversion from liraglutide monotherapy to BOT therapy after 3 months of liraglutide monotherapy CONDITION: type 2 diabetes mellitus PRIMARY OUTCOME: The levels of HbA1c and blood glucose obtained by SMBG SECONDARY OUTCOME: body weight, the frequency of hypoglycemia and lipid profiles INCLUSION CRITERIA: Type 2 diabetic patients treated with BOT therapy
Epistemonikos ID: 1b7212b780b144761c7ecdd1a28eb57563bff340
First added on: Aug 22, 2024